Company Filing History:
Years Active: 2018
Title: Manabu Kurokawa: Innovator in Cancer Therapeutics
Introduction
Manabu Kurokawa is a prominent inventor based in Durham, NC (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. His work focuses on identifying and utilizing MDM2 inhibitors, which are crucial in developing effective cancer therapeutics.
Latest Patents
Kurokawa holds a patent for "Methods of identifying and using MDM2 inhibitors." This patent outlines methods for treating subjects with cancer and screening for MDM2 inhibitors that may serve as effective cancer therapeutics. The cancers targeted by these methods include those that may become resistant to treatment with tyrosine kinase inhibitors. His research provides methods for treating cancers that exhibit elevated levels of MDM2, Mcl-1, or PP5, or decreased levels of Huwe1 or CAS using MDM2 inhibitors. These inhibitors may be effective in treating these cancers alone or in combination with a tyrosine kinase inhibitor, regardless of the p53 status of the cancer.
Career Highlights
Kurokawa is affiliated with Duke University, where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential to improve treatment outcomes for patients with resistant cancers.
Collaborations
Some of his notable coworkers include Sally A. Kornbluth and Neil Lee Spector, who have collaborated with him on various research projects.
Conclusion
Manabu Kurokawa's innovative work in identifying MDM2 inhibitors represents a significant advancement in cancer treatment. His contributions have the potential to change the landscape of cancer therapeutics and improve patient outcomes.